Vitamin D3 - Total Wellness Booster

Vitamin D increases its benefits when used consistently over a 4 week period of time. ​
Health Benefits of Vitamin D Injections. Part of maintaining a healthy body and attractive appearance comes down to a proper balance of vitamins and minerals. These nutrients help boost your immune system, protect against infection and illnesses, and keep your body running properly.  Part of maintaining a healthy body and attractive appearance comes down to a proper balance of vitamins and minerals. These nutrients help boost your immune system, protect against infection and illnesses, and keep your body running properly. But with so many vitamins to keep in balance, it is common to be deficient in one or two areas. Frequently, a healthy intake of vitamin D is ignored. This can lead to a variety of medical complications and poor overall health. Because of this, it is important to know both the symptoms of and treatment options for vitamin D deficiency.
Boosting Wellbeing with Vitamin D
​Vitamin D is absorbed into the body through both diet and exposure to the sun. Due to busy schedules and more time than ever spent indoors, however, many people are suffering from vitamin D deficiency. What makes this nutrient so important is the vital role it plays in helping the human body absorb essential nutrients from food such as calcium, iron, and zinc.
People with a vitamin D deficiency are at risk for cardiovascular disease, weakened bones, skeletal deformities, cognitive impairments, asthma, and cancer. Whether you are currently dealing with these conditions or are at risk, proper amounts of vitamin D can help you get back to better health.

Conditions Regularly Treated: ​
  • Vitamin D is a powerful vitamin that is actually a hormone
  • Most of us are very deficient in Vitamin D
  • Can help in many conditions – these are just a few:
  • Obesity
  • Fibromyalgia
  • Osteoporosis
  • Thyroid problems
  • ​Additional Benefits 
Clinical Research
​1. Hofbauer LC, Dunstan CR, Spelsberg TC, Riggs BL, Khosla S. Osteoprotegerin production by human osteoblast lineage cells is stimulated by vitamin D, bone morphogenetic protein-2, and cytokines. Biochem Biophys Res Commun. 1998;250:776–781. [PubMed] [Google Scholar]
2. Lin J, Manson JE, Lee IM, Cook NR, Buring JE, Zhang SM. Intakes of calcium and vitamin D and breast cancer risk in women. Arch Intern Med. 2007;167:1050–1059. [PubMed] [Google Scholar]
3. Kamen D, Aranow C. Vitamin D in systemic lupus erythematosus. Curr Opin Rheumatol. 2008;20:532–537. [PubMed] [Google Scholar]
4. Judd SE, Tangpricha V. Vitamin D deficiency and risk for cardiovascular disease. Am J Med Sci. 2009;338:40–44. [PMC free article] [PubMed] [Google Scholar]
5. Choi HS, Kim KA, Lim CY, Rhee SY, Hwang YC, Kim KM, et al. Low serum vitamin D is associated with high risk of diabetes in Korean adults. J Nutr. 2011;141:1524–1528. [PubMed] [Google Scholar]
6. Yu S, Fang H, Han J, Cheng X, Xia L, Li S, et al. The high prevalence of hypovitaminosis D in China: a multicenter vitamin D status survey. Medicine (Baltimore) 2015;94:e585. [PMC free article] [PubMed] [Google Scholar]
7. Rizzoli R, Eisman JA, Norquist J, Ljunggren O, Krishnarajah G, Lim SK, et al. Risk factors for vitamin D inadequacy among women with osteoporosis: an international epidemiological study. Int J Clin Pract. 2006;60:1013–1019. [PubMed] [Google Scholar]
8. Anderson PH, May BK, Morris HA. Vitamin D metabolism: new concepts and clinical implications. Clin Biochem Rev. 2003;24:13–26. [PMC free article] [PubMed] [Google Scholar]
9. Jurutka PW, Bartik L, Whitfield GK, Mathern DR, Barthel TK, Gurevich M, et al. Vitamin D receptor: key roles in bone mineral pathophysiology, molecular mechanism of action, and novel nutritional ligands. J Bone Miner Res. 2007;22(Suppl 2):V2–V10. [PubMed] [Google Scholar]
10. Heikinheimo RJ, Inkovaara JA, Harju EJ, Haavisto MV, Kaarela RH, Kataja JM, et al. Annual injection of vitamin D and fractures of aged bones. Calcif Tissue Int. 1992;51:105–110. [PubMed] [Google Scholar]
11. Shimada T, Hasegawa H, Yamazaki Y, Muto T, Hino R, Takeuchi Y, et al. FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res. 2004;19:429–435. [PubMed] [Google Scholar]
12. Liu S, Tang W, Zhou J, Stubbs JR, Luo Q, Pi M, et al. Fibroblast growth factor 23 is a counter-regulatory phosphaturic hormone for vitamin D. J Am Soc Nephrol. 2006;17:1305–1315. [PubMed] [Google Scholar]
13. Seiler S, Reichart B, Roth D, Seibert E, Fliser D, Heine GH. FGF-23 and future cardiovascular events in patients with chronic kidney disease before initiation of dialysis treatment. Nephrol Dial Transplant. 2010;25:3983–3989. [PubMed] [Google Scholar]
14. Faul C, Amaral AP, Oskouei B, Hu MC, Sloan A, Isakova T, et al. FGF23 induces left ventricular hypertrophy. J Clin Invest. 2011;121:4393–4408. [PMC free article] [PubMed] [Google Scholar]
15. Nasrallah MM, El-Shehaby AR, Salem MM, Osman NA, El Sheikh E, Sharaf El Din UA. Fibroblast growth factor-23 (FGF-23) is independently correlated to aortic calcification in haemodialysis patients. Nephrol Dial Transplant. 2010;25:2679–2685. [PubMed] [Google Scholar]
16. Turner C, Dalton N, Inaoui R, Fogelman I, Fraser WD, Hampson G. Effect of a 300,000-IU loading dose of ergocalciferol (vitamin D2) on circulating 1,25(OH)2-vitamin D and fibroblast growth factor-23 (FGF-23) in vitamin D insufficiency. J Clin Endocrinol Metab. 2013;98:550–556. [PubMed] [Google Scholar]
17. Atkins GJ, Rowe PS, Lim HP, Welldon KJ, Ormsby R, Wijenayaka AR, et al. Sclerostin is a locally acting regulator of late-osteoblast/preosteocyte differentiation and regulates mineralization through a MEPE-ASARM-dependent mechanism. J Bone Miner Res. 2011;26:1425–1436. [PMC free article] [PubMed] [Google Scholar]
18. Morvan F, Boulukos K, Clement-Lacroix P, Roman Roman S, Suc-Royer I, Vayssiere B, et al. Deletion of a single allele of the Dkk1 gene leads to an increase in bone formation and bone mass. J Bone Miner Res. 2006;21:934–945. [PubMed] [Google Scholar]
19. Sankaralingam A, Roplekar R, Turner C, Dalton RN, Hampson G. Changes in dickkopf-1 (DKK1) and sclerostin following a loading dose of vitamin D 2 (300,000 IU) J Osteoporos. 2014;2014:682763. [PMC free article] [PubMed] [Google Scholar]
20. Acibucu F, Dokmetas HS, Acibucu DO, Kilicli F, Aydemir M, Cakmak E. Effect of vitamin D treatment on serum sclerostin level. Exp Clin Endocrinol Diabetes. 2017;125:634–637. [PubMed] [Google Scholar]
21. Chung YS, Chung DJ, Kang MI, Kim IJ, Koh JM, Min YK, et al. Vitamin D repletion in Korean postmenopausal women with osteoporosis. Yonsei Med J. 2016;57:923–927. [PMC free article] [PubMed] [Google Scholar]
22. Burns J, Paterson CR. Single dose vitamin D treatment for osteomalacia in the elderly. Br Med J (Clin Res Ed) 1985;290:281–282. [PMC free article] [PubMed] [Google Scholar]
23. Saito H, Maeda A, Ohtomo S, Hirata M, Kusano K, Kato S, et al. Circulating FGF-23 is regulated by 1alpha,25-dihydroxyvitamin D3 and phosphorus in vivo. J Biol Chem. 2005;280:2543–2549. [PubMed] [Google Scholar]
24. Uzum AK, Salman S, Telci A, Boztepe H, Tanakol R, Alagol F, et al. Effects of vitamin D replacement therapy on serum FGF23 concentrations in vitamin D-deficient women in short term. Eur J Endocrinol. 2010;163:825–831. [PubMed] [Google Scholar]
25. Wolf M, Koch TA, Bregman DB. Effects of iron deficiency anemia and its treatment on fibroblast growth factor 23 and phosphate homeostasis in women. J Bone Miner Res. 2013;28:1793–1803. [PubMed] [Google Scholar]
26. Wolf M, White KE. Coupling fibroblast growth factor 23 production and cleavage: iron deficiency, rickets, and kidney disease. Curr Opin Nephrol Hypertens. 2014;23:411–419. [PMC free article] [PubMed] [Google Scholar]
27. Romagnoli E, Mascia ML, Cipriani C, Fassino V, Mazzei F, D'Erasmo E, et al. Short and long-term variations in serum calciotropic hormones after a single very large dose of ergocalciferol (vitamin D2) or cholecalciferol (vitamin D3) in the elderly. J Clin Endocrinol Metab. 2008;93:3015–3020. [PubMed] [Google Scholar]
28. Gatti D, Viapiana O, Fracassi E, Idolazzi L, Dartizio C, Povino MR, et al. Sclerostin and DKK1 in postmenopausal osteoporosis treated with denosumab. J Bone Miner Res. 2012;27:2259–2263. [PubMed] [Google Scholar]
29. Gatti D, Viapiana O, Adami S, Idolazzi L, Fracassi E, Rossini M. Bisphosphonate treatment of postmenopausal osteoporosis is associated with a dose dependent increase in serum sclerostin. Bone. 2012;50:739–742. [PubMed] [Google Scholar]